CEA Industries (Nasdaq: VAPE) and 10X Capital, with the support of YZi Labs, announce a $500M private placement (including $100M in crypto) to establish the world’s largest publicly listed BNB-focused treasury company. The deal, set to close by July 31, could reach $1.25B with warrant exercises. Over 140 institutions joined, including Pantera, GSR, dao5, and Arrington. https://t.co/ifhviM9B1q ...

Core Viewpoint - Organogenesis Holdings Inc. has entered into a Subscription Agreement with Avista Healthcare Partners for the sale of Series A Convertible Preferred Stock, raising gross proceeds of $130 million to fund strategic growth initiatives and share repurchase [1][2]. Financial Details - The net proceeds from the private placement will be allocated to various strategic growth initiatives, including operating activities, clinical development, working capital, capital expenditures, debt repayment, and general corporate purposes [2]. - Approximately $23.5 million of the net proceeds will be used to repurchase 7,421,731 shares of Class A common stock at a price of $3.1597 per share, based on the 10-day trailing volume weighted average price as of November 11, 2024 [2]. Corporate Governance - Garrett Lustig has been appointed to the Board of Directors, effective November 12, 2024. He is a Principal at Avista Healthcare Partners and has experience in various private companies [3]. Strategic Partnership - The investment from Avista is seen as a validation of Organogenesis' growth potential, providing strategic capital to enhance the company's balance sheet and financial flexibility [4]. - Avista Healthcare Partners emphasizes its belief in Organogenesis' mission to improve healthcare through innovative solutions [4]. Preferred Stock Details - The Preferred Stock is convertible into common stock at an initial rate of 263.7358 shares per $1,000 of liquidation preference, equating to a conversion price of $3.79 per share, which is a 20% premium to the 10-day trailing volume weighted average price [5]. - Investors have the right to redeem the Preferred Stock for its liquidation preference after seven years from issuance [6]. - An 8% cumulative annual dividend will be paid to investors, compounding quarterly, with voting rights on an as-converted basis [7].